View Future GrowthCanBas 과거 순이익 실적과거 기준 점검 0/6CanBas 의 수입은 연평균 -15.8%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 13.4%의 비율로 증가했습니다. 매출은 연평균 93.7%의 비율로 감소해 왔습니다.핵심 정보-15.80%순이익 성장률3.82%주당순이익(EPS) 성장률Biotechs 산업 성장률31.91%매출 성장률-93.68%자기자본이익률-57.84%순이익률n/a다음 순이익 업데이트12 Aug 2026최근 과거 실적 업데이트공시 • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2026 Results on Aug 12, 2026CanBas Co., Ltd. announced that they will report fiscal year 2026 results on Aug 12, 2026공시 • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026CanBas Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026공시 • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2025 Results on Aug 08, 2025CanBas Co., Ltd. announced that they will report fiscal year 2025 results on Aug 08, 2025공시 • Aug 28+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2025 Results on Feb 13, 2025CanBas Co., Ltd. announced that they will report Q2, 2025 results on Feb 13, 2025공시 • Jun 05CanBas Co., Ltd. to Report Fiscal Year 2024 Results on Aug 09, 2024CanBas Co., Ltd. announced that they will report fiscal year 2024 results on Aug 09, 2024공시 • Sep 03+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2024 Results on May 10, 2024CanBas Co., Ltd. announced that they will report Q3, 2024 results on May 10, 2024모든 업데이트 보기Recent updates공시 • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2026 Results on Aug 12, 2026CanBas Co., Ltd. announced that they will report fiscal year 2026 results on Aug 12, 2026분석 기사 • May 20Is CanBas (TSE:4575) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...New Risk • Mar 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.7b (US$93.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥14.7b market cap, or US$93.3m).분석 기사 • Feb 03We Think CanBas (TSE:4575) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...New Risk • Nov 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.3b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥15.3b market cap, or US$99.9m).공시 • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026CanBas Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026공시 • Aug 08CanBas Co., Ltd., Annual General Meeting, Sep 29, 2025CanBas Co., Ltd., Annual General Meeting, Sep 29, 2025.공시 • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2025 Results on Aug 08, 2025CanBas Co., Ltd. announced that they will report fiscal year 2025 results on Aug 08, 2025분석 기사 • Apr 08CanBas (TSE:4575) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.2b (US$97.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥14.2b market cap, or US$97.1m).분석 기사 • Dec 16Here's Why We're Not Too Worried About CanBas' (TSE:4575) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...공시 • Aug 28+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2025 Results on Feb 13, 2025CanBas Co., Ltd. announced that they will report Q2, 2025 results on Feb 13, 2025공시 • Aug 09CanBas Co., Ltd., Annual General Meeting, Sep 27, 2024CanBas Co., Ltd., Annual General Meeting, Sep 27, 2024.분석 기사 • Jun 26CanBas (TSE:4575) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...공시 • Jun 05CanBas Co., Ltd. to Report Fiscal Year 2024 Results on Aug 09, 2024CanBas Co., Ltd. announced that they will report fiscal year 2024 results on Aug 09, 2024분석 기사 • Feb 26We're Hopeful That CanBas (TSE:4575) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...New Risk • Feb 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.7b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (JP¥14.7b market cap, or US$99.8m).New Risk • Oct 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (24% increase in shares outstanding).공시 • Sep 03+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2024 Results on May 10, 2024CanBas Co., Ltd. announced that they will report Q3, 2024 results on May 10, 2024New Risk • Aug 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Share price has been highly volatile over the past 3 months (7.5% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m.New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.4b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).공시 • Aug 12CanBas Co., Ltd., Annual General Meeting, Sep 26, 2023CanBas Co., Ltd., Annual General Meeting, Sep 26, 2023.New Risk • Aug 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).공시 • Jun 03+ 1 more updateCanBas Co., Ltd. to Report Fiscal Year 2023 Results on Aug 10, 2023CanBas Co., Ltd. announced that they will report fiscal year 2023 results on Aug 10, 2023공시 • May 20CanBas Co., Ltd. announced that it expects to receive ¥729 million in fundingCanBas Co., Ltd. announced a private placement of 500,000 common shares at an issue price of ¥1,458 per share for the gross proceeds of ¥729,000,000 on May 18, 2023. The transaction will include participation from new investors Long Corridor Alpha Opportunities Master Fund and MAP246 Segregated Portfolio. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company. The transaction is expected to close on June 2, 2023.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (5 non-independent directors). Independent External Director Toshio Furuta was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2023 Results on May 12, 2023CanBas Co., Ltd. announced that they will report Q3, 2023 results on May 12, 2023Reported Earnings • Aug 15Full year 2022 earnings released: JP¥88.26 loss per share (vs JP¥70.01 loss in FY 2021)Full year 2022 results: JP¥88.26 loss per share (down from JP¥70.01 loss in FY 2021). Net loss: JP¥855.0m (loss widened 61% from FY 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.공시 • Aug 14CanBas Co., Ltd., Annual General Meeting, Sep 27, 2022CanBas Co., Ltd., Annual General Meeting, Sep 27, 2022.공시 • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2022 Results on Aug 12, 2022CanBas Co., Ltd. announced that they will report fiscal year 2022 results on Aug 12, 2022Reported Earnings • May 19Third quarter 2022 earnings released: JP¥22.78 loss per share (vs JP¥9.24 loss in 3Q 2021)Third quarter 2022 results: JP¥22.78 loss per share (down from JP¥9.24 loss in 3Q 2021). Net loss: JP¥224.0m (loss widened 215% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (5 non-independent directors). Independent External Director Toshio Furuta was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 12First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: JP¥39.87 loss per share (up from JP¥43.73 loss in 1H 2021). Net loss: JP¥359.0m (loss widened 16% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 12First quarter 2022 earnings released: JP¥22.38 loss per share (vs JP¥29.76 loss in 1Q 2021)First quarter 2022 results: Net loss: JP¥198.0m (loss narrowed 5.7% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.공시 • Sep 03CanBas Co., Ltd. announced that it expects to receive ¥16.38843 million in fundingCanBas Co., Ltd. announced a private placement of 55,554 units at a price of ¥295 for gross proceeds of ¥16,388,430 on September 2, 2021. The company has issued through 17th Stock Acquisition Rights. As part of the transaction, no monetary payment is required in exchange for the bonds with Stock Acquisition Rights.Reported Earnings • May 17Third quarter 2021 earnings released: JP¥9.24 loss per share (vs JP¥19.46 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were flat. Third quarter 2021 results: Revenue: JP¥27.0m (flat on 3Q 2020). Net loss: JP¥71.0m (loss narrowed 47% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 14Second quarter 2021 earnings released: JP¥14.04 loss per share (vs JP¥18.59 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: JP¥28.0m (flat on 2Q 2020). Net loss: JP¥100.0m (loss narrowed 21% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 05New 90-day low: JP¥426The company is down 40% from its price of JP¥710 on 07 October 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period.Is New 90 Day High Low • Dec 16New 90-day low: JP¥457The company is down 35% from its price of JP¥703 on 17 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.공시 • Nov 06CanBas Co., Ltd. announced that it expects to receive ¥9.678321 million in funding from Advantage Partners, Inc. and other investorsCanBas Co., Ltd. (TSE:4575) announced that it will issue 17,629 16th Stock Acquisition Rights at a price of ¥549 per stock acquisition right for the gross proceeds of ¥9,678,321 on November 5, 2020. The stock acquisition rights are converted into 1,762,900 common shares and have initial exercise of ¥610 per share and minimum exercise price of ¥305 per share. The expected fund raise through exercise of stock acquisition right are ¥1,085,047,321. The transaction include participation from existing investor Inflexion II Fund L.P., funds managed by Advantage Partners, Inc. for 4,524 stock acquisition rights, Investment Limited Partnership InfleXion II for 11,612 stock acquisition rights and Flagship Asset Management Investment Association No. 90 for 1,493 stock acquisition rights.공시 • Sep 12CanBas Co., Ltd. to Report Q1, 2021 Results on Nov 13, 2020CanBas Co., Ltd. announced that they will report Q1, 2021 results on Nov 13, 2020매출 및 비용 세부 내역CanBas가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TSE:4575 매출, 비용 및 순이익 (JPY Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-1,199207031 Dec 250-1,245204030 Sep 250-1,209197030 Jun 250-1,157194031 Mar 250-1,487194031 Dec 240-1,296190030 Sep 240-1,311191030 Jun 240-1,209191031 Mar 240-1,086210031 Dec 230-1,074205030 Sep 230-1,116196030 Jun 230-1,244184031 Mar 230-983182031 Dec 220-1,059176030 Sep 220-979176030 Jun 220-855175031 Mar 2226-733185031 Dec 2153-580183030 Sep 2181-519182030 Jun 21108-531174031 Mar 21110-548179031 Dec 20110-610176030 Sep 20110-637178030 Jun 20110-572186031 Mar 20109-516184031 Dec 19109-571180030 Sep 19109-492166030 Jun 19115-456161031 Mar 19116-486172031 Dec 18116-435180030 Sep 18116-508189030 Jun 18110-532191031 Mar 18109-528197031 Dec 17109-463193030 Sep 17109-415193030 Jun 17109-419190031 Mar 17110-374196031 Dec 16110-485188030 Sep 16107-480173030 Jun 16105-414167031 Mar 16101-384182031 Dec 1599-255179030 Sep 1585-256182030 Jun 1560-2661780양질의 수익: 4575 은(는) 현재 수익성이 없습니다.이익 마진 증가: 4575는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 4575은 수익성이 없으며 지난 5년 동안 손실이 연평균 15.8% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 4575의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 4575은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(4.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 4575는 현재 수익성이 없으므로 자본 수익률이 음수(-57.84%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/25 18:27종가2026/06/25 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CanBas Co., Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kiyokazu YamazakiIchiyoshi Research Institute Inc.
공시 • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2026 Results on Aug 12, 2026CanBas Co., Ltd. announced that they will report fiscal year 2026 results on Aug 12, 2026
공시 • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026CanBas Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026
공시 • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2025 Results on Aug 08, 2025CanBas Co., Ltd. announced that they will report fiscal year 2025 results on Aug 08, 2025
공시 • Aug 28+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2025 Results on Feb 13, 2025CanBas Co., Ltd. announced that they will report Q2, 2025 results on Feb 13, 2025
공시 • Jun 05CanBas Co., Ltd. to Report Fiscal Year 2024 Results on Aug 09, 2024CanBas Co., Ltd. announced that they will report fiscal year 2024 results on Aug 09, 2024
공시 • Sep 03+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2024 Results on May 10, 2024CanBas Co., Ltd. announced that they will report Q3, 2024 results on May 10, 2024
공시 • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2026 Results on Aug 12, 2026CanBas Co., Ltd. announced that they will report fiscal year 2026 results on Aug 12, 2026
분석 기사 • May 20Is CanBas (TSE:4575) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
New Risk • Mar 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.7b (US$93.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥14.7b market cap, or US$93.3m).
분석 기사 • Feb 03We Think CanBas (TSE:4575) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
New Risk • Nov 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.3b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥15.3b market cap, or US$99.9m).
공시 • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026CanBas Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026
공시 • Aug 08CanBas Co., Ltd., Annual General Meeting, Sep 29, 2025CanBas Co., Ltd., Annual General Meeting, Sep 29, 2025.
공시 • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2025 Results on Aug 08, 2025CanBas Co., Ltd. announced that they will report fiscal year 2025 results on Aug 08, 2025
분석 기사 • Apr 08CanBas (TSE:4575) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...
New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.2b (US$97.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥14.2b market cap, or US$97.1m).
분석 기사 • Dec 16Here's Why We're Not Too Worried About CanBas' (TSE:4575) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
공시 • Aug 28+ 2 more updatesCanBas Co., Ltd. to Report Q2, 2025 Results on Feb 13, 2025CanBas Co., Ltd. announced that they will report Q2, 2025 results on Feb 13, 2025
공시 • Aug 09CanBas Co., Ltd., Annual General Meeting, Sep 27, 2024CanBas Co., Ltd., Annual General Meeting, Sep 27, 2024.
분석 기사 • Jun 26CanBas (TSE:4575) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
공시 • Jun 05CanBas Co., Ltd. to Report Fiscal Year 2024 Results on Aug 09, 2024CanBas Co., Ltd. announced that they will report fiscal year 2024 results on Aug 09, 2024
분석 기사 • Feb 26We're Hopeful That CanBas (TSE:4575) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
New Risk • Feb 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.7b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (JP¥14.7b market cap, or US$99.8m).
New Risk • Oct 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (24% increase in shares outstanding).
공시 • Sep 03+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2024 Results on May 10, 2024CanBas Co., Ltd. announced that they will report Q3, 2024 results on May 10, 2024
New Risk • Aug 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Share price has been highly volatile over the past 3 months (7.5% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m.
New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.4b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.4b free cash flow). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).
공시 • Aug 12CanBas Co., Ltd., Annual General Meeting, Sep 26, 2023CanBas Co., Ltd., Annual General Meeting, Sep 26, 2023.
New Risk • Aug 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).
공시 • Jun 03+ 1 more updateCanBas Co., Ltd. to Report Fiscal Year 2023 Results on Aug 10, 2023CanBas Co., Ltd. announced that they will report fiscal year 2023 results on Aug 10, 2023
공시 • May 20CanBas Co., Ltd. announced that it expects to receive ¥729 million in fundingCanBas Co., Ltd. announced a private placement of 500,000 common shares at an issue price of ¥1,458 per share for the gross proceeds of ¥729,000,000 on May 18, 2023. The transaction will include participation from new investors Long Corridor Alpha Opportunities Master Fund and MAP246 Segregated Portfolio. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company. The transaction is expected to close on June 2, 2023.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (5 non-independent directors). Independent External Director Toshio Furuta was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Sep 01+ 2 more updatesCanBas Co., Ltd. to Report Q3, 2023 Results on May 12, 2023CanBas Co., Ltd. announced that they will report Q3, 2023 results on May 12, 2023
Reported Earnings • Aug 15Full year 2022 earnings released: JP¥88.26 loss per share (vs JP¥70.01 loss in FY 2021)Full year 2022 results: JP¥88.26 loss per share (down from JP¥70.01 loss in FY 2021). Net loss: JP¥855.0m (loss widened 61% from FY 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
공시 • Aug 14CanBas Co., Ltd., Annual General Meeting, Sep 27, 2022CanBas Co., Ltd., Annual General Meeting, Sep 27, 2022.
공시 • Jun 03CanBas Co., Ltd. to Report Fiscal Year 2022 Results on Aug 12, 2022CanBas Co., Ltd. announced that they will report fiscal year 2022 results on Aug 12, 2022
Reported Earnings • May 19Third quarter 2022 earnings released: JP¥22.78 loss per share (vs JP¥9.24 loss in 3Q 2021)Third quarter 2022 results: JP¥22.78 loss per share (down from JP¥9.24 loss in 3Q 2021). Net loss: JP¥224.0m (loss widened 215% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (5 non-independent directors). Independent External Director Toshio Furuta was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 12First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: JP¥39.87 loss per share (up from JP¥43.73 loss in 1H 2021). Net loss: JP¥359.0m (loss widened 16% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 12First quarter 2022 earnings released: JP¥22.38 loss per share (vs JP¥29.76 loss in 1Q 2021)First quarter 2022 results: Net loss: JP¥198.0m (loss narrowed 5.7% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
공시 • Sep 03CanBas Co., Ltd. announced that it expects to receive ¥16.38843 million in fundingCanBas Co., Ltd. announced a private placement of 55,554 units at a price of ¥295 for gross proceeds of ¥16,388,430 on September 2, 2021. The company has issued through 17th Stock Acquisition Rights. As part of the transaction, no monetary payment is required in exchange for the bonds with Stock Acquisition Rights.
Reported Earnings • May 17Third quarter 2021 earnings released: JP¥9.24 loss per share (vs JP¥19.46 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were flat. Third quarter 2021 results: Revenue: JP¥27.0m (flat on 3Q 2020). Net loss: JP¥71.0m (loss narrowed 47% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 14Second quarter 2021 earnings released: JP¥14.04 loss per share (vs JP¥18.59 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: JP¥28.0m (flat on 2Q 2020). Net loss: JP¥100.0m (loss narrowed 21% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 05New 90-day low: JP¥426The company is down 40% from its price of JP¥710 on 07 October 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period.
Is New 90 Day High Low • Dec 16New 90-day low: JP¥457The company is down 35% from its price of JP¥703 on 17 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
공시 • Nov 06CanBas Co., Ltd. announced that it expects to receive ¥9.678321 million in funding from Advantage Partners, Inc. and other investorsCanBas Co., Ltd. (TSE:4575) announced that it will issue 17,629 16th Stock Acquisition Rights at a price of ¥549 per stock acquisition right for the gross proceeds of ¥9,678,321 on November 5, 2020. The stock acquisition rights are converted into 1,762,900 common shares and have initial exercise of ¥610 per share and minimum exercise price of ¥305 per share. The expected fund raise through exercise of stock acquisition right are ¥1,085,047,321. The transaction include participation from existing investor Inflexion II Fund L.P., funds managed by Advantage Partners, Inc. for 4,524 stock acquisition rights, Investment Limited Partnership InfleXion II for 11,612 stock acquisition rights and Flagship Asset Management Investment Association No. 90 for 1,493 stock acquisition rights.
공시 • Sep 12CanBas Co., Ltd. to Report Q1, 2021 Results on Nov 13, 2020CanBas Co., Ltd. announced that they will report Q1, 2021 results on Nov 13, 2020